Navana Pharmaceuticals PLC announcements
122 Dhaka Stock Exchange announcements for Navana Pharmaceuticals PLC (NAVANAPHAR) since 2022: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (23).
- Emphasis of Matters
The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Navana%20Pharmaceuticals%20PLC_2025.pdf
- Credit Rating Result
National Credit Ratings Limited (NCR) has assigned the surveillance entity rating of the Company as "AA" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements as on June 30, 2025 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record Date
Trading of the shares of the company will resume on 20.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 19.11.2025.
- Q1 Financials
(Q1 Un-audited): Diluted EPS was Tk. 1.69 for July-September 2025. EPS was Tk. 1.71 for July-September 2025 as against Tk. 1.25 for July-September 2024. NOCFPS was Tk. 5.08 for July-September 2025 as against Tk. 2.00 for July-September 2024. NAV per share was Tk. 47.03 as on September 30, 2025 and Tk. 45.29 as on June 30, 2025. (cont.) (Cont. News of NAVANAPHAR): Reasons for deviation: Net Profit after Tax has increased significantly due to the increment of Net Sales and Gross Profit as well as reduction of finance cost, as a result Earnings per Share (EPS) increased by 62.40% from the previous year. Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 5.08 from Tk. 2.00, because of cash received from the customers was higher than the cash payment to the vendors and others in the reporting period. (end)
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 17.11.2025 to 18.11.2025 and trading of the shares will remain suspended on record date i.e., 19.11.2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Navana Pharmaceuticals PLC submitted auditor's report regarding "Status of IPO (Initial Public Offering) Proceeds utilization statement" for the quarter ended September?30,?2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Navana-Pharma-ceuticals-PLC-2025.pdf
- NAVANAPHARM: Dividend Declaration
The Board of Directors has recommended 14% Cash Dividend only for general shareholders for the year ended June 30, 2025. Sponsor shareholders and Directors holding 33,989,714 shares. Total payable to General Shareholders is Tk. 47,524,499.40. Date of AGM: 31.12.2025, Time: 3:00 PM, Venue: Hybrid (Physical: Green Hall, Jolshiri Golf Club, Jolshiri Abashon, Sector-17, Rupganj, Narayanganj; Virtual: Will be notified later). Record Date: 19.11.2025. (cont.) (cont. news of NAVANAPHARM): The Company has also reported EPS of Tk. 4.54, NAV per share of Tk. 45.29 and NOCFPS of Tk. 16.90 for the year ended June 30, 2025 as against EPS of Tk. 3.77, NAV per share of Tk. 42.46 and NOCFPS of Tk. 6.58 for the year ended June 30, 2024. (end)
- NAVANAPHARM: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Decision to repay subscribed amount of Convertible Bond earlier
The company has informed that the Board of Directors of the company in its meeting held on 1st September, 2025 has decided to repay the subscribed amount of Navana Pharmaceuticals Partial Convertible Bond earlier than maturity without any conversion due to the under subscription, subject to the approval from Bangladesh Securities and Exchange commission.
- Auditor's report regarding status of IPO Proceeds utilization
Navana Pharmaceuticals PLC. submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended on June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Navana%20Pharma_2025.pdf
- Appointment of Chairman
The company has informed that Mrs. Saiqa Mazed has been appointed as the Chairman of the Board of the company with effect from June 24, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Navana Pharmaceuticals PLC submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended 31 March, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Navana%20Pharma_25.pdf
- Change of corporate office address of the company
The company has informed that the Board of Directors has decided to change the corporate office of the company to the following new address at 99 Gulshan Avenue, Rupayan Golden Age, 6th Floor, Plot-6, Block-CWN(C), Dhaka-1212. The change is effective immediately.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 1.01 for January-March 2025 as against Tk. 1.00 for January-March 2024; EPS was Tk. 3.49 for July 2024-March 2025 as against Tk. 3.09 for July 2023-March 2024. NOCFPS was Tk. 10.22 for July 2024-March 2025 as against Tk. 1.59 for July 2023-March 2024. NAV per share was Tk. 45.32 as on March 31, 2025 and Tk. 42.46 as on June 30, 2024. (cont.) (cont. news of NAVANAPHAR): Reasons of significant deviation in EPS and NOCFPS between the periods: EPS: Increment of Earnings per Share in the reporting period by 12.94% because of growth of Sales Revenue as well as optimum cost management policy. NOCFPS: NOCFPS has increased to Tk. 10.22 from Tk. 1.59, due to cash received from the customers was higher than the cash payment for operation in the reporting period. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Navana Pharmaceuticals PLC submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended December 31, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/NAVANAPHAR_2024.pdf
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 1.00 for October-December 2024 as against Tk. 0.98 for October-December 2023; EPS was Tk. 2.25 for July-December 2024 as against Tk. 2.09 for July-December 2023. NOCFPS was Tk. 3.16 for July-December 2024 as against Tk. 0.87 for July-December 2023. NAV per share was Tk. 44.10 as on December 31, 2024 and Tk. 42.46 as on June 30, 2024. NOCFPS has been increased due to cash received from customers was higher than cash payment to the vendors in the reporting period.
- Decision to establish a herbal division at the factory premises
The company has informed that the Board of Directors of the company in its meeting held on January 15, 2025 has decided to establish a herbal division at the factory premises subject to the approval of concerned regulators, whereas total footprint area will be 10,000 sq.ft. approximately. (cont.) (Cont. news of NAVANAPHAR): Total project cost will be around BDT 208.50 Million, to be financed through company's internal and external sources. Once operational, which will generate additional around BDT 400 Million revenue in its first year. The project is anticipated to be completed within five years. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.